Journal
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
Volume 29, Issue 4, Pages 670-674Publisher
SAGE PUBLICATIONS INC
DOI: 10.1038/jcbfm.2009.3
Keywords
middle cerebral artery occlusion (MCAO); minocycline; poly(ADP-ribose) polymerase (PARP); sex differences
Categories
Funding
- NIH [R01 NS050505, NS055215]
Ask authors/readers for more resources
Minocycline is neuroprotective in clinical and experimental stroke studies, due in part to its ability to inhibit poly (ADP-ribose) polymerase. Previous preclinical data have shown that interference with poly (ADP-ribose) polymerase signaling leads to sex-specific neuroprotection, reducing stroke injury only in males. In this study, we show that minocycline is ineffective at reducing ischemic damage in females after middle cerebral artery occlusion, likely due to effects on poly (ADP-ribose) polymerase signaling. Clinical trials must consider possible sex differences in the response to neuroprotective agents, if we hope to translate promising therapies to stroke patients of both sexes. Journal of Cerebral Blood Flow & Metabolism ( 2009) 29, 670-674; doi:10.1038/jcbfm.2009.3; published online 4 February 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available